June 24 Quick Takes: CSL pays $450M for uniQure’s hemophilia gene therapy; plus Merck-Yumanity, Editas, Compass-Olivia, Century-Empirica, Tetraphase-La Jolla

CSL gets global rights to uniQure gene therapy
CSL Ltd. (ASX:CSL) is paying $450 million up front for an exclusive, worldwide license to commercialize etranacogene dezaparvovec (AMT-061) from uniQure N.V. (NASDAQ:QURE), which is also eligible for undisclosed milestones and royalties. uniQure is responsible for completing the

Read the full 459 word article

How to gain access

Continue reading with a
two-week free trial.